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REGULATION OF INFLAMMATION BY ENDOGENOUS DANGER
SIGNALS IN TISSUE INJURY AND ARTHRITIS
A.M. Piccinini. Kennedy Inst. of Rheumatology, Nufﬁeld Dept. of
Orthopaedics, Rheumatology and Musculoskeletal Sci., Univ. of Oxford,
Oxford, United Kingdom
Inﬂammation is now recognized as an important component of the
pathophysiology of a number of diseases that were historically regarded
as non-inﬂammatory, including atherosclerosis, osteoarthritis, cancer
and metabolic disorders like type 2 diabetes. In these conditions,
inﬂammation occurs in the absence of any pathogen and is therefore
deﬁned as sterile inﬂammation. This raises the question: what are the
inciting sterile stimuli and the host receptors that mediate this
inﬂammatory response? During recent years, it has become increas-
ingly accepted that the immune system is designed to combat danger
posed by both infection and injury, rather than to merely recognize
non-self. Evolutionarily conserved pattern recognition receptors (PRRs)
sense danger signals generated upon infection (pathogen-associated
molecular patterns - PAMPs) and endogenous molecules created upon
tissue injury (damage-associated molecular patterns - DAMPs) and, in
response, activate inﬂammatory signalling pathways. DAMPs include
intracellular molecules released from necrotic cells, extracellular matrix
(ECM) fragments and ECM molecules upregulated upon injury. DAMPs
are vital for tissue repair, however, compelling evidence from both
human studies and experimental animal models suggests that DAMPs
are also implicated in inﬂammatory diseases such as rheumatoid
arthritis. Here, in an attempt to initiate repair, they induce the pro-
duction of inﬂammatory mediators that trigger further tissue damage
establishing a vicious cycle that contributes to the persistence of
inﬂammation. This talk will discuss what is known about the molecular
mechanisms by which this network of diverse endogenous danger
signals, and their receptors, drives inﬂammation, discuss whether
DAMPs also stimulate inﬂammation in osteoarthritis and ask if there is
any interplay between endogenous danger signals and other inﬂam-
matory mediators. Here I will focus on the latest, at times controversial,
developments in the understanding of these inﬂammatory pathways
and highlight their relevance in arthritis.
I-11
THE INTERACTIONS OF OSTEOARTHRITIS WITH OTHER COMMON
CONDITIONS
G.A. Hawker. Univ. of Toronto, Toronto, ON, Canada
World-wide, there has been an unprecedented rise in the number of
persons living with obesity and well into old age, and thus with mul-
tiple chronic conditions. Among the most common conditions are dia-
betes mellitus (DM), cardiovascular disease (CVD), hypertension (HT),
and osteoarthritis (OA), which commonly co-occur. Currently, it is
estimated that as many as 90% of individuals aged 65þ years with OA
are living with at least one other chronic condition. Although less well
studied, the prevalence of OA in people with DM, CVD and HT also
appears to be high. ‘Arthritis’ and painful hips/knees limiting activity,
suggesting OA, have been reported in 50-60% of people with heart
disease or DM. The conﬂuence of these conditions in obese patients
with knee OA has led to the concept of ‘metabolic OA’ and to studies
examining both the role of inﬂammatory adiopokines in the patho-
genesis of OA, as well as the impact of OA on outcomes of these other
common chronic conditions. This presentation will highlight key ﬁnd-
ings and future directions for this research.
I-12
TOWARDS BETTER ANIMAL MODELS OF OA PAIN WITH HIGHER
TRANSLATIONAL VALUE
J.J. McDougall. Dalhousie Univ., Halifax, NS, Canada
Purpose: The primary concern of patients living with osteoarthritis
(OA) is chronic intractable pain. Current drug therapies are only mod-
erately effective in a subset of patients and long-term use of these drugs
can be risky. Thus, there is an urgent need for new, efﬁcacious analgesics
which will provide pain relief for all OA patients. One of the main
hurdles in developing novel therapeutics to treat OA pain is the clinical
relevance of the animal models used to test the drugs. All OA models
recapitulate only some of the features of the disease and eachmodel has
advantages and limitations. Furthermore, OA is not a homogeneousdisease and the pain associated with the various types of OA can vary
from patient to patient. Some forms of OA have a strong inﬂammatory
component, for example, which may be managed by anti-inﬂamma-
tories such as non-steroidal anti-inﬂammatory drugs (NSAIDs). Other
OA patients are NSAID-insensitive and the source of their pain may
stem from damage to the peripheral nervous system. This sub-
population of OA patients may respond better to neuropathic pain
analgesics such as gabapentin [1]. Repicating all of these variables in a
single animal model is impossible, therefore, multiple models must be
considered.
Pain assessment in animal models is also complex and often open to
subjective interpretation [2]. The majority of behavioural tests rely on
evoked pain responses to an experimenter-applied stimulus (e.g. von
Frey hairs, pressure activators). These approaches provide useful
information regarding reﬂex mechanosensitivity with little consid-
eration for affect. Pain tests that rely on noxious thermal stimuli have
also been used to test OA pain behaviour; however, the clinical rele-
vance of these tests is moot. Spontaneous OA pain is typically measured
by gait analysis, weight bearing, grip strength, and activity levels. Since
rodents are prey animals, these spontaneous behaviours are often
concealed to avoid predation making their experimental quantiﬁcation
somewhat erratic. Electrophysiological recording of nerve activity has
proven to be a powerful means of testing analgesics and unraveling
neurophysiological processes in the pain pathway [3]. While these
techniques give valuable, objective measures of nociception, they do
not give a universal measure of pain per se.
This workshop will summarize and evaluate the various animal models
of OA (chemical, surgical, spontaneous) and discuss their relative ben-
eﬁts for investigating OA pain. Participants will discuss how to improve
the translational value of current and future preclinical models of OA
pain.
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OA TRIAL BANK
S. Bierma-Zeinstra, M. van Middelkoop. OA Trial Bank Steering Group,
Univ. Med. Ctr. Rotterdam, Rotterdam, Netherlands
Purpose: Based on small to moderate effect sizes for the wide range of
symptomatic treatments in osteoarthritis (OA), and on the hetero-
geneity of OA patients, treatment guidelines for OA have stressed the
need for research on clinical predictors of response to different treat-
ments. Meta-analysis of individual patient data (IPD) of worldwide
available RCTs would allow us to robustly identify subgroups that
speciﬁcally response to certain treatment. The initiative to collect and
analyze IPD in OA research is commenced by the OA Trial Bank, which is
endorsed by the OARSI and the EULAR. The OA Trial Bank will bring
together data from individuals with OA recruited to different clinical
trials from different countries around the world to form a databank.
Potential subgroups of patients for different interventions in OA
patients will be predeﬁned and will be analyzed with IPD. The proce-
dures within the OA Trial Bank enable clinical OA researchers world-
wide to initiate new research proposals and become involved in the OA
Trial Bank.
Methods: This workshop will inform about the OA Trial Bank organ-
ization, its legal procedures for data transfer, and the methods used for
setting the objectives and performing data analyses. Secondly, the
workshop will show an example based on the ﬁrst IPD analyses from
randomized trials studying the effect of intra-articular glucocorticoid
injections in patients with hip or knee OA. Thirdly, by means of inter-
active procedures, subgroup identiﬁcation for other interventions will
be discussed and the workshop participants will learn how they can
become involved in the OA Trail Bank.
